胍丁胺通过ISLR调控NF-κB信号通路抑制肠道细胞焦亡减轻脓毒症肠损伤
该研究结合生物信息学分析、动物实验和细胞实验探讨胍丁胺减轻脓毒症肠损伤的机制。生物信息学分析GSE13904数据集发现脓毒症患者ISLR表达显著降低;盲肠结扎穿孔(CLP)脓毒症小鼠肠组织ISLR mRNA和蛋白表达均显著低于假手术组。细胞实验中,胍丁胺可上调LPS损伤细胞的ISLR表达、下调NLRP3、IL-1β、caspase-1表达并减少IL-6、IL-1β、TNF-α释放;siRNA-ISLR或NF-κB激活剂Aconine可逆转胍丁胺的上述效应。结论提示胍丁胺可能通过ISLR调控NF-κB信号通路抑制肠道细胞焦亡。
要点
- 生物信息学分析GSE13904数据集显示脓毒症患者血中ISLR表达显著降低,提示其可能参与脓毒症病理过程。
- CLP脓毒症小鼠肠组织ISLR mRNA(2-ΔΔCt)0.52±0.12 vs 假手术组1.02±0.21,ISLR/GAPDH 0.55±0.01 vs 1.00±0.01,均P<0.05。
- LPS+胍丁胺组较LPS组ISLR mRNA(2-ΔΔCt)0.98±0.17 vs 0.48±0.11、ISLR/GAPDH 0.95±0.08 vs 0.71±0.05升高,NLRP3、IL-1β、caspase-1及上清IL-6、IL-1β、TNF-α降低(均P<0.05)。
- siRNA-ISLR或NF-κB激活剂Aconine可逆转胍丁胺对ISLR、NLRP3、IL-1β、caspase-1及上清IL-6、IL-1β、TNF-α的效应(均P<0.05)。
- 作者结论认为胍丁胺可能通过ISLR调控NF-κB信号通路抑制肠道细胞焦亡,从而减轻脓毒症肠损伤。
适用人群与场景
- 生物信息学分析对象为GEO数据库GSE13904数据集中脓毒症患者的血液转录组数据。
- 动物实验对象为C57BL/6J小鼠,随机分为假手术组(仅开腹不结扎)和脓毒症肠损伤模型组(盲肠结扎穿孔CLP),每组5只。
- 细胞实验对象为ICE-6细胞,分为对照组、LPS组、LPS+胍丁胺组、LPS+胍丁胺+siRNA-ISLR组,以及对照组、LPS组、LPS+胍丁胺组、LPS+胍丁胺+Aconine组。
诊断标准与关键阈值
- 细胞损伤模型建立:ICE-6细胞在含10 mg/L脂多糖的完全培养基中培养为LPS组。
- siRNA-ISLR沉默效果验证:与对照组和siRNA-NC组比较,siRNA-ISLR组ISLR表达下调,确认ISLR基因被特异性敲低。
- LPS损伤模型建立成功标准:与对照组比较,LPS组ISLR表达显著下调,NLRP3、IL-1β、caspase-1表达显著上调,上清IL-6、IL-1β、TNF-α水平显著升高(均P<0.05)。
处置流程与药物剂量
- 动物实验:小鼠建模成功后48小时安乐死并取回肠组织,用qPCR和Western blotting检测ISLR表达。
- 细胞实验:LPS+胍丁胺组在LPS组基础上给予120 μmol/L胍丁胺处理。
- 细胞实验:LPS+胍丁胺+siRNA-ISLR组在LPS+胍丁胺组基础上转染siRNA-ISLR。
- 细胞实验:LPS+胍丁胺+Aconine组在LPS+胍丁胺组基础上给予0.25 mmol/L Aconine(NF-κB信号激活剂)处理。
- 检测指标:用qPCR和Western blotting检测ISLR、NLRP3、IL-1β、caspase-1表达,用酶联免疫吸附试验检测细胞上清IL-6、IL-1β、TNF-α水平。
研究设计与关键结果
- 研究类型为基础研究,包含生物信息学分析、动物实验(每组5只C57BL/6J小鼠)和细胞实验。
- 生物信息学分析:GSE13904数据集的GO、KEGG和PPI分析显示脓毒症患者多种分子异常表达,其中ISLR表达显著降低。
- 动物实验:脓毒症肠损伤模型组肠组织ISLR mRNA(2-ΔΔCt)0.52±0.12 vs 假手术组1.02±0.21,ISLR/GAPDH 0.55±0.01 vs 1.00±0.01,均P<0.05,与生物信息学分析趋势一致,故选ISLR为目标分子。
- 细胞实验:与LPS组比较,LPS+胍丁胺组ISLR mRNA(2-ΔΔCt)0.98±0.17 vs 0.48±0.11、ISLR/GAPDH 0.95±0.08 vs 0.71±0.05显著上调,NLRP3、IL-1β、caspase-1表达显著下调,上清IL-6、IL-1β、TNF-α显著降低(均P<0.05)。
- 细胞实验:与LPS+胍丁胺组比较,LPS+胍丁胺+siRNA-ISLR组ISLR mRNA(2-ΔΔCt)0.62±0.20 vs 0.98±0.17、ISLR/GAPDH 0.68±0.03 vs 0.95±0.08显著下调,NLRP3、IL-1β、caspase-1表达显著上调,上清IL-6、IL-1β、TNF-α显著升高(均P<0.05)。
- 细胞实验:与LPS+胍丁胺组比较,LPS+胍丁胺+Aconine组ISLR mRNA(2-ΔΔCt)0.28±0.05 vs 0.97±0.31、ISLR/GAPDH 0.61±0.03 vs 0.93±0.03显著下调,NLRP3、IL-1β、caspase-1表达显著上调,上清IL-6、IL-1β、TNF-α显著升高(均P<0.05),提示siRNA-ISLR或NF-κB信号激活剂可逆转胍丁胺的效应。
证据类型、等级与局限
- 证据类型:基础研究,包括生物信息学分析、动物实验和细胞实验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该研究为生物信息学分析、小鼠实验和细胞实验,作者结论认为胍丁胺可能通过ISLR调控NF-κB信号通路抑制肠道细胞焦亡,从而减轻脓毒症肠损伤,尚未提供急诊或ICU临床应用推荐。
- 原文未据此给出临床实践建议。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the mechanism by which agmatine alleviates sepsis-induced intestinal injury through the inhibition of intestinal pyroptosis.
METHODS: 1) Bioinformatic analysis: Dataset GSE13904 was selected from the gene expression omnibus (GEO) database, gene ontology (GO), Kyoto encyclopedia of genes and genomes database (KEGG), and protein-protein interaction (PPI) analyses were performed to analyze transcriptomic changes in the blood of sepsis patients. 2) Animal experiments: Ten C57BL/6J mice were randomly divided into a sham group (laparotomy only without ligation) and a sepsis-induced intestinal injury model group [cecal ligation and puncture (CLP)], with 5 mice in each group. Mice were euthanized 48 hours after successful modeling, and ileal tissues were harvested. The expression of immunoglobulin superfamily containing leucine rich repeat (ISLR) in the intestinal tissues of mice was detected by quantitative polymerase chain reaction (qPCR) and Western blotting. 3) Cell experiments: ICE-6 cells were divided into the following groups: control group (cultured in complete medium), lipopolysaccharide (LPS) group (cultured in complete medium containing 10 mg/L lipopolysaccharide, LPS), LPS+agmatine group (treated with 120 μmol/L agmatine on the basis of the LPS group), and an LPS+agmatine+siRNA-ISLR group [transfected with small interfering RNA (siRNA)-ISLR on the basis of the LPS + agmatine group]. Furthermore, cells transfected with siRNA negative control (siRNA-NC) were used to verify the silencing effect of siRNA-ISLR on the ISLR gene. ICE-6 cells were divided into a control group, an LPS group, an LPS+agmatine group, and an LPS+agmatine+Aconine group [treated with 0.25 mmol/L Aconine, a nuclear factor-κB (NF-κB) signaling activator, on the basis of the LPS + agmatine group]. The expression levels of ISLR, NOD-like receptor protein 3 (NLRP3), interleukin-1β (IL-1β), and caspase-1 in cells from each group were detected by qPCR and Western blotting. The levels of IL-6, IL-1β, and tumor necrosis factor-α (TNF-α) in the cell supernatants were measured by enzyme-linked immunosorbent assay (ELISA).
RESULTS: 1) Bioinformatic analysis: GO, KEGG, and PPI analyses of dataset GSE13904 revealed abnormal expression of multiple molecules in sepsis patients, among which ISLR expression was significantly decreased. 2) Animal experiments: The expression levels of ISLR in the intestinal tissue of mice in the sepsis-induced intestinal injury model group were significantly lower than those in the sham group [ISLR mRNA (2-ΔΔCt): 0.52±0.12 vs. 1.02±0.21; ISLR/GAPDH: 0.55±0.01 vs. 1.00±0.01, both P < 0.05], which was consistent with the trend observed in the bioinformatic analysis; therefore, ISLR was selected as the target molecule for functional and mechanistic investigation. 3) Cell experiments: Compared with the control and siRNA-NC groups, ISLR expression was downregulated in the siRNA-ISLR group, confirming successful specific knockdown of the ISLR gene. Compared with the control group, ISLR expression was significantly downregulated in the LPS group, while the expression of NLRP3, IL-1β, and caspase-1 was significantly upregulated, and the levels of IL-6, IL-1β, and TNF-α in the supernatant were significantly increased (all P < 0.05), indicating successful establishment of the LPS-induced injury model. Compared with the LPS group, ISLR expression was significantly upregulated in the LPS+agmatine group [ISLR mRNA (2-ΔΔCt): 0.98±0.17 vs. 0.48±0.11, ISLR/GAPDH: 0.95±0.08 vs. 0.71±0.05], while the expression of NLRP3, IL-1β, and caspase-1 was significantly downregulated, and the levels of IL-6, IL-1β, and TNF-α in the supernatant were significantly decreased (all P < 0.05). Compared with the LPS+agmatine group, ISLR expression was significantly downregulated in both the LPS+agmatine+siRNA-ISLR group [ISLR mRNA (2-ΔΔCt): 0.62±0.20 vs. 0.98±0.17, ISLR/GAPDH: 0.68±0.03 vs. 0.95±0.08] and the LPS+agmatine+Aconine group [ISLR mRNA (2-ΔΔCt): 0.28±0.05 vs. 0.97±0.31, ISLR/GAPDH: 0.61±0.03 vs. 0.93±0.03], while the expression of NLRP3, IL-1β, and caspase-1 was significantly upregulated, and the levels of IL-6, IL-1β, and TNF-α in the supernatant were significantly increased (all P < 0.05), suggesting that the effects of agmatine were reversed by either siRNA-ISLR or the NF-κB signaling activator.
CONCLUSIONS: Agmatine may alleviate sepsis-induced intestinal cell injury by inhibiting intestinal cell pyroptosis, potentially through regulating NF-κB signaling via ISLR.
参考来源
- Zhang E, Tian Y, Yang B, et al. [Agmatine alleviates sepsis-induced intestinal injury by modulating the nuclear factor-ΚB signaling pathway through immunoglobulin superfamily containing leucine rich repeat to suppress intestinal pyroptosis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2025. PMID: 41500685. doi:10.3760/cma.j.cn121430-20250730-00411
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。